TMEM37 is a transmembrane protein that functions as a calcium channel modulator with disease relevance across multiple conditions. Functionally, TMEM37 stabilizes calcium channels in an inactivated state and modulates calcium current when coexpressed with CACNA1G [UniProt annotation]. In pancreatic beta cells, TMEM37 inhibits Ca2+-influx and reduces insulin secretion, representing a novel dysregulated gene in type 2 diabetic islets 1. This transcriptomic signature distinguishes type 2 diabetes from other hyperglycemic conditions, with TMEM37 enriched in gene co-expression modules correlated with impaired insulin secretion 1. Beyond metabolic disease, TMEM37 was identified as an independent disease-free survival prognostic gene in colon cancer patients, suggesting potential clinical utility in cancer prognosis 2. Additionally, TMEM37 emerged as an optimal feature gene in thyroid-associated ophthalmopathy and was associated with lipid metabolism pathways implicated in autoimmune eye disease pathogenesis 3. In breast cancer, TMEM37 was identified as a gene subject to promoter methylation-based silencing in mammary carcinomas 4, indicating epigenetic dysregulation in malignancy. These findings position TMEM37 as a multifunctional protein with roles in calcium signaling, metabolic homeostasis, and cancer biology, with potential clinical applications in prognostic biomarker development.